Abstract
Background Acute generalized exanthematous pustulosis (AGEP) is rare cutaneous drug reaction involving drug-specific T lymphocytes and neutrophilic inflammation. Imatinib is a tyrosine kinase inhibitor used widely in treatment of chronic myeloid leukemia (CML). Rash is a common side effect of imatinib, occurring in up to 30% of patients. However, there are only two case reports to date describing AGEP secondary to imatinib.
Highlights
Acute generalized exanthematous pustulosis (AGEP) is rare cutaneous drug reaction involving drug-specific T lymphocytes and neutrophilic inflammation
Rash is a common side effect of imatinib, occurring in up to 30% of patients
There are only two case reports to date describing AGEP secondary to imatinib
Summary
Acute generalized exanthematous pustulosis (AGEP) is rare cutaneous drug reaction involving drug-specific T lymphocytes and neutrophilic inflammation. From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2014 Ottawa, ON, Canada. Background Acute generalized exanthematous pustulosis (AGEP) is rare cutaneous drug reaction involving drug-specific T lymphocytes and neutrophilic inflammation. Imatinib is a tyrosine kinase inhibitor used widely in treatment of chronic myeloid leukemia (CML). Rash is a common side effect of imatinib, occurring in up to 30% of patients.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
